Jinyu Bio-Technology Co., Ltd.

Jinyu Bio-Technology Co., Ltd. has recently undergone an evaluation adjustment reflecting its market position. The company displays a premium valuation with notable financial metrics, despite challenges in management efficiency. Over the past year, it has significantly outperformed the broader market, showcasing both strengths and areas for improvement.

Jinyu Bio-Technology Co., Ltd. saw a significant intraday increase on June 29, 2026, outperforming the China Shanghai Composite. However, the company faces long-term growth challenges, with declining net sales and negative quarterly results. Its low return on capital employed highlights profitability concerns within the pharmaceuticals and biotechnology sector.

Jinyu Bio-Technology Co., Ltd. has faced significant stock declines, contrasting with the broader market's modest gains. The company has reported negative results for four consecutive quarters, low profitability metrics, and a high Price to Book ratio, raising concerns about its financial health within the pharmaceuticals and biotechnology sector.

Jinyu Bio-Technology Co., Ltd. saw a significant intraday increase on June 8, 2026, contrasting with a decline in the broader market. Over the past year, the company has outperformed the China Shanghai Composite, though it has faced recent challenges, including declines in stock performance and profitability metrics.

Jinyu Bio-Technology Co., Ltd. saw a significant stock decline today, contrasting with the broader market. The company has struggled recently, reporting negative results for four consecutive quarters and experiencing declines in net sales and operating profit. Despite a strong annual return, its financial metrics indicate limited profitability.

Jinyu Bio-Technology Co., Ltd. saw a significant stock price drop today, reflecting ongoing volatility. Despite a strong annual performance, year-to-date results indicate a decline. The company faces profitability challenges, evidenced by low ROCE and ROE, and has reported negative results for the last four quarters.

Jinyu Bio-Technology Co., Ltd. faced a significant decline today, marking a challenging week with a total drop of 4.86%. The company has struggled with profitability, reflected in low financial metrics and negative results over the past four quarters, raising concerns about its market position in the Pharmaceuticals & Biotechnology sector.

Jinyu Bio-Technology Co., Ltd. saw a significant intraday increase on March 24, 2026, despite a recent decline over the past week and month. The company has demonstrated strong annual performance, with an 87.35% return, although it faces challenges in profitability and declining sales trends.

Jinyu Bio-Technology Co., Ltd. saw a notable stock decline today, contrasting with the broader market's performance. Despite recent setbacks, the company has achieved a strong annual return. However, it faces challenges in management efficiency and has reported negative results for four consecutive quarters, raising concerns about its valuation.

Jinyu Bio-Technology Co., Ltd. saw a notable rise in stock performance on March 18, 2026, reaching an intraday high. The company has outperformed the China Shanghai Composite over the past week and year, but faces challenges in management efficiency and long-term growth, with declining net sales and operating profit.

Jinyu Bio-Technology Co., Ltd. saw a significant stock decline today, contrasting with the broader market. Despite a strong annual return, the company has struggled recently with negative results and declining sales. Its market capitalization is CNY 17,377 million, indicating a large-cap status in the Pharmaceuticals & Biotechnology sector.